Guus_Geluk schreef op 15 april 2014 11:18:
Ik weet niet of het hier al eens gepost is maar ik heb een mooi document gevonden:
PHARM: Management Meeting and Approval
in Israel;
Target Upped to $3A discussion with management indicated a flurry of background activities
ahead of the April PDUFA for Ruconest. Additionally, Pharming announced
that partner MegaPharm received marketing authorization and reimbursement
approval for Ruconest in Israel. All eyes remain on the April 2014 PDUFA date
for Ruconest in the U.S.
Reiterate Buy and raising price target to $3 from $2.roth2.bluematrix.com/sellside/EmailDo...